Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators.

@article{Cleland1997EffectOR,
  title={Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators.},
  author={John George Franklin Cleland and Leif Rw Erhardt and Gordon D. Murray and Alistair S. Hall and S. G. Ball},
  journal={European heart journal},
  year={1997},
  volume={18 1},
  pages={
          41-51
        }
}
BACKGROUND The importance of the effects of ACE inhibitors on sudden death, progressive heart failure and recurrent infarction to the reduction in overall mortality in heart failure and after myocardial infarction is disputed. METHODS The AIRE study randomized 2006 patients with clinical or radiological evidence of heart failure within 2-9 days of a myocardial infarction to receive ramipiril 5 mg b.d. or matching placebo. Outcomes were assessed independently by members of an end-points… 

Figures and Tables from this paper

ACE inhibitors in heart failure: effect on mode of death.
TLDR
A comprehensive meta-analysis for all completed, published or unpublished randomized, placebo-controlled trials of ACE inhibitors revealed a significant reduction in total mortality and in the combined endpoint of mortality and hospitalization for congestive heart failure and similar benefits were observed with different ACE inhibitors.
Mode of death in heart failure: findings from the ATLAS trial
TLDR
The use of competing risks analysis on the data from the ATLAS study has identified variables associated with certain modes of death in heart failure patients that may make it possible to predict which patients might benefit most from particular therapeutic interventions.
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
TLDR
LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure, which accounted for the majority of cardiovascular deaths.
Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials.
TLDR
CRT alone as compared with optimal medical therapy reduces all-cause mortality in patients with advanced HF and predominantly reduces worsening HF mortality, not affecting SCD.
Adverse Effects of ACE Inhibitors in Patients with Chronic Heart Failure and/or Ventricular Dysfunction
TLDR
Cough, hypotension, renal dysfunction, dizziness, hyperkalaemia, and impotence were all significantly more prevalent among patients treated with ACE inhibitors than among those in the control groups.
Ramipril: a review of its use in the prevention of cardiovascular outcomes.
TLDR
Ramipril 10 mg/day can significantly reduce the incidence of MI, stroke or death from cardiovascular causes in patients aged > or =55 years who are at increased risk for the development of ischaemic cardiovascular events due to a history of stroke, coronary artery disease, diabetes mellitus plus at least one other risk factor or peripheral vascular disease.
...
...

References

SHOWING 1-10 OF 23 REFERENCES
Validation of primary and secondary outcomes and classification of mode of death among patients with clinical evidence of heart failure after a myocardial infarction: a report from the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.
TLDR
The AIRE study--a trial involving over 2,000 patients with clinical heart failure after myocardial infarction--assessed different outcomes, and an end-points committee reviewed all data following preset definitions prior to code break to obtain maximum quality in the validation of outcomes.
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
TLDR
In patients with asymptomatic left ventricular dysfunction after myocardial infarction, long-term administration of captopril was associated with an improvement in survival and reduced morbidity and mortality due to major cardiovascular events.
Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators.
TLDR
The finding that the recurrence of MI was independent ofLeft ventricular ejection fraction suggests that captopril could be useful in preventing recurrent MI in patients with more preserved left ventricular function and either an anti-ischemic effect or the ability to modify the atherosclerotic process in survivors of MI.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
TLDR
The addition of enalapril to conventional therapy significantly reduced mortality and hospitalizations for heart failure in patients with chronic congestive heart failure and reduced ejection fractions.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
  • Medicine
    The New England journal of medicine
  • 1987
TLDR
It is concluded that the addition of enalapril to conventional therapy in patients with severe congestive heart failure can reduce mortality and improve symptoms and a significant improvement in NYHA classification was observed in the enAlapril group.
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
TLDR
Long-term treatment with trandolapril in patients with reduced left ventricular function soon after myocardial infarction significantly reduced the risk of overall mortality, mortality from cardiovascular causes, sudden death, and the development of severe heart failure.
Mechanism of Death in Heart Failure The Vasodilator‐Heart Failure Trials
TLDR
Although mechanistically distinct terminal events can be identified in patients with heart failure and physiological measurements can provide some insight into the risk of these disparate events, sudden death and pump failure death both appear largely to be linked to the severity of cardiac dysfunction and symptoms.
How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodelling, resetting, or sudden death?
TLDR
The clinical nature of left ventricular remodelling is reevaluate and to what extent it accounts for the beneficial effects of ACE inhibitors on outcome in patients with established ventricular dysfunction with or without heart failure is considered.
...
...